Abstract
Photodynamic and sonodynamic therapy (PDT, SDT) are modern, non-invasive treatments applicable to different types of cancer. PHOTOGLIOBLASTER aims to develop innovative, minimally invasive strategies for the efficient and selective delivery of photo- or sono-activable sensitizers to tumor cells using recombinant viral vectors for the treatment of Glioblastoma (GBM), using two approaches. The first strategy will arm a neuro-attenuated oHSV-1 with the protein KillerRed (KR) under the control of a tumor specific promoter, to clear those oHSV-1 infected cells that have escaped from viral killing with PDT. The second strategy is based on the M13 phage, engineered to target cells expressing the glioma-specific variant of the EGFR receptor and rigged with hundreds of sensitizer molecules, excitable with deep penetrating infrared light or ultrasound. Successful results are expected to pave the road for innovative PDT/SDT cancer therapeutics with broad translational potential.
Project details
Unibo Team Leader: Alberto Danielli
Unibo involved Department/s:
Dipartimento di Farmacia e Biotecnologie
Coordinator:
Università degli Studi di PADOVA(Italy)
Total Unibo Contribution: Euro (EUR) 54.223,00
Project Duration in months: 24
Start Date:
12/10/2023
End Date:
28/02/2026
